Your session is about to expire
← Back to Search
Part B - LT3001 and Aspirin for Stroke
Phase 1
Waitlist Available
Research Sponsored by Lumosa Therapeutics Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 days
Awards & highlights
Study Summary
This study is evaluating whether a drug may have the potential to help individuals with a certain type of cancer.
Eligible Conditions
- Stroke
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 16 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of adverse events
Secondary outcome measures
Changes from baseline in coagulation
Changes from baseline in platelet function test
Plasma PK parameters of Apixaban - AUC
+14 moreTrial Design
6Treatment groups
Experimental Treatment
Placebo Group
Group I: Part B - LT3001 and DabigatranExperimental Treatment2 Interventions
Multiple doses of LT3001 and Dabigatran administered
Group II: Part B - LT3001 and ClopidogrelExperimental Treatment2 Interventions
Multiple doses of LT3001 and Clopidogrel administered
Group III: Part B - LT3001 and AspirinExperimental Treatment2 Interventions
Multiple doses of LT3001 and Aspirin administered
Group IV: Part B - LT3001 and ApixabanExperimental Treatment2 Interventions
Multiple doses of LT3001 and Apixaban administered
Group V: Part A - LT3001 Drug ProductExperimental Treatment1 Intervention
Multiple doses of LT3001 administered by intravenous infusion
Group VI: Part A - PlaceboPlacebo Group1 Intervention
Multiple doses of Placebo administered by intravenous infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clopidogrel
FDA approved
Apixaban
FDA approved
Acetylsalicylic acid
FDA approved
Dabigatran
FDA approved
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Lumosa Therapeutics Co., Ltd.Lead Sponsor
7 Previous Clinical Trials
625 Total Patients Enrolled
Mimi Yeh, PhDStudy DirectorLumosa Phase 1 unit
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger